Drug intelligence / Profile preview

XB2001 + liposomal irinotecan + 5-fluorouracil + leucovorin

Development stage: Unknown
Lead developer: XBiotech
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This is a **combination regimen** consisting of XB2001 (an investigational monoclonal antibody targeting Connective Tissue Growth Factor, CTGF), liposomal irinotecan (Onivyde, a liposomal formulation of irinotecan—a topoisomerase I inhibitor), 5-fluorouracil (a thymidylate synthase inhibitor), and leucovorin (folinic acid, which stabilizes the bond of 5-FU with TS). Liposomal irinotecan with 5-fluorouracil and leucovorin is an approved regimen for metastatic pancreatic cancer after progression on gemcitabine-based therapy[1][3][4]. XB2001 is being studied in combination with this backbone for its potential to target tumor stroma and improve chemotherapy delivery. The mechanism of the regimen combines cytotoxic activity against tumor DNA/RNA synthesis (5-FU, irinotecan), modulation of chemotherapy activity (leucovorin), and possible anti-stroma, anti-CTGF effects (XB2001 if included). Indication: being studied primarily for pancreatic adenocarcinoma.

Brand names: Onivyde
Other names: Irinotecan liposomal + 5-fluorouracil + leucovorinONIVYDE + 5-fluorouracil + leucovorin

Targets

TS (Thymidylate synthase)CTGF (Connective tissue growth factor)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on XB2001 + liposomal irinotecan + 5-fluorouracil + leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XB2001 + liposomal irinotecan + 5-fluorouracil + leucovorin.

Explore the full profile